Alejandro Cane

Dr. Alejandro Cane


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
VWVerna Welch
Verna Welch
TMTom Metcalf
Tom Metcalf
RMRichard Macey
Richard Macey
KMKristen Markus
Kristen Markus
ASAmy J. Sears
Amy J. Sears
TWTimothy Lee Wiemken
Timothy Lee Wiemken
Influenza is a common respiratory infection associated with a substantial clinical, humanistic, and economic burden globally. Vaccines are essential to prevent and control influenza and are recommended by public-health agencies, such as the WHO and US CDC; however, vaccination rates vary considerably across the globe. This review aimed to investigate the perceived barriers and attitudes to influenza vaccination in the global population, in order to identify strategies that may improve influenza vaccination coverage. A structured literature search was undertaken to identify studies that reported on patient-reported attitudes towards influenza vaccination, focused on the adult general population in 16 prespecified countries. Eighty studies were included in this review. Negative attitude towards healthcare were found to be the most agreed upon barrier to vaccine uptake (31.1% agreement). The most agreed promoter of influenza vaccination was trust in healthcare services (62.0% agreement). Approximately 50% of participants intended to receive the influenza vaccine in the following season. To improve influenza vaccination coverage, healthcare workers must strengthen the foundation of substantial trust in healthcare services and provide educational materials that improve influenza vaccination knowledge among the adult general population.


1 March 2019 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
JPJessica Presa
Jessica Presa
RARodrigo Sini de Almeida
Rodrigo Sini de Almeida
JSJulia Spinardi
Julia Spinardi
ACAlejandro Cane
Alejandro Cane
The aim of this study was to evaluate the epidemiological profile of invasive meningococcal disease (IMD) in Brazil, the first Latin American country to introduce the group C meningococcal conjugate vaccine (included in the vaccination schedule in 2010). A systematic review was conducted, covering the years 2005-2017, to identify epidemiological information on IMD and Neisseria meningitidis carriers in Brazil. Documents from the Brazilian Ministry of Health and two public databases were analyzed to determine annual incidence rates, absolute numbers of diagnosed cases, serogroups identified, the relative distribution of cases per serogroup, and the case fatality rate (CFR). Sixteen studies were selected. The incidence rate ranged from 0.88 to 5.3 cases per 100000 inhabitants per year. According to secondary data, the annual incidence of IMD in 2015 was highest in males <1year old (7.1/100000). The number of diagnosed cases declined significantly over the years. In the literature, IMD showed a CFR from 20.0% to 50.0%, and a higher CFR for serogroup W (17.8%). Secondary data showed an absolute reduction in meningitis-attributable deaths between 2007 and 2015; however, the CFR remained stable (11.1% in 2007 and 8.4% in 2015). In 2015, serogroup W showed the highest CFR (24.1%), followed by serogroups C (19.2%), B (17.7%), and Y (14.3%). Despite a reduction in cases, the CFR remained stable and similar in the different age groups, even for disease caused by different serogroups. The highest CFR was found to be associated with serogroup W.

29 November 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
JFJaime Fergie
Jaime Fergie
MMMary M. Moran
Mary M. Moran
ACAlejandro Cane
Alejandro Cane
SPShanti Pather
Shanti Pather
ӦTӦzlem Türeci
Ӧzlem Türeci
ASAmit Srivastava
Amit Srivastava
Although pediatric populations experienced lower COVID-19 severity and mortality than adults, the epidemiology of this disease continues to evolve. COVID-19 clinical manifestations in pediatrics commonly include fever and cough, but may differ from adults and by variant. Serious complications, including MIS-C, rarely occur. Although early data showed a decreased likelihood of COVID-19 transmission from children versus adults, outbreaks and viral shedding studies support pediatric transmission potential. Children may mount more robust initial immune responses to SARS-CoV-2 versus adults. COVID-19 vaccines with available pediatric data include BNT162b2, mRNA-1273, CoronaVac, and BBIBP-CorV. Depending on age group and jurisdiction, BNT162b2 and mRNA-1273 have received full approval or emergency/conditional authorization in the United States and European Union from 6 months of age. Clinical trials have shown BNT162b2 and mRNA-1273 safety and high efficacy in pediatric populations, with demonstrably noninferior immune responses versus young adults. Real-world studies further support BNT162b2 safety and effectiveness against the Delta variant. mRNA vaccination benefits are considered to outweigh risks, including myocarditis; however, pediatric vaccination rates remain relatively low. Given a growing body of clinical trial and real-world data showing vaccine safety and effectiveness, pediatric vaccination should be prioritized as an important strategy to control the pandemic.

11 September 2023 in Frontiers in Pediatrics
Verified
Journal Article
Open access
LMLeah J. McGrath
Leah J. McGrath
MMMary M. Moran
Mary M. Moran
TATamuno Alfred
Tamuno Alfred
MRMaya Reimbaeva
Maya Reimbaeva
MDManuela DiFusco
Manuela DiFusco
SLSantiago M. C. Lopez
Santiago M. C. Lopez
Introduction: We compared hospitalization outcomes of young children hospitalized with COVID-19 to those hospitalized with influenza in the United States.Methods: Patients aged 0-<5 years hospitalized with an admission diagnosis of acute COVID-19 (April 2021-March 2022) or influenza (April 2019-March 2020) were selected from the PINC AI Healthcare Database Special Release. Hospitalization outcomes included length of stay (LOS), intensive care unit (ICU) admission, oxygen supplementation, and mechanical ventilation (MV). Inverse probability of treatment weighting was used to adjust for confounders in logistic regression analyses.Results: Among children hospitalized with COVID-19 (n = 4,839; median age: 0 years), 21.3% had an ICU admission, 19.6% received oxygen supplementation, 7.9% received MV support, and 0.5% died. Among children hospitalized with influenza (n = 4,349; median age: 1 year), 17.4% were admitted to the ICU, 26.7% received oxygen supplementation, 7.6% received MV support, and 0.3% died. Compared to children hospitalized with influenza, those with COVID-19 were more likely to have an ICU admission (adjusted odds ratio [aOR]: 1.34; 95% confidence interval [CI]: 1.21–1.48). However, children with COVID-19 were less likely to receive oxygen supplementation (aOR: 0.71; 95% CI: 0.64–0.78), have a prolonged LOS (aOR: 0.81; 95% CI: 0.75–0.88), or a prolonged ICU stay (aOR: 0.56; 95% CI: 0.46–0.68). The likelihood of receiving MV was similar (aOR: 0.94; 95% CI: 0.81, 1.1).Conclusions: Hospitalized children with either SARS-CoV-2 or influenza had severe complications including ICU admission and oxygen supplementation. Nearly 10% received MV support. Both SARS-CoV-2 and influenza have the potential to cause severe illness in young children.

23 May 2025 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Open access
KAKathleen M. PhD Andersen
Kathleen M. PhD Andersen
TPThomas M. Mba Porter
Thomas M. Mba Porter
DFDeshayne B. PhD Fell
Deshayne B. PhD Fell
MRMaya Reimbaeva
Maya Reimbaeva
MMMary M. Moran
Mary M. Moran
SLSantiago M. C. Lopez
Santiago M. C. Lopez
Background: This study aimed to compare the clinical burden among young children hospitalized for respiratory syncytial virus (RSV) to coronavirus disease 2019 (COVID-19) or influenza. Methods: Patients <5 years of age hospitalized for RSV, COVID-19 or influenza between September 2022—August 2024 were selected from the PINC-AI Healthcare Database for retrospective cohort analysis. Hospitalization outcomes included length of stay, supplemental oxygen use, intensive care unit (ICU) admission, invasive mechanical ventilation (IMV) and inhospital death. Weighted robust Poisson regression models estimated risk ratios with 95% confidence intervals comparing RSV to COVID-19 and influenza, with further stratification by age at admission (<1, 1 and 2–4 years). Results: Among 56,634 children (43,766 RSV; 6,697 COVID-19; 6,171 influenza) hospitalized for the acute respiratory infections, children hospitalized for RSV were mean age 0.7 years, versus 0.7 (COVID-19) and 1.7 years (influenza), more often admitted to the ICU (28.2%, vs. 22.4% and 21.7%), required supplemental oxygen (46.1%, vs. 20.2% and 26.2%) and IMV (12.0%, vs. 8.3% and 8.2%). In adjusted regression models, increased risks of supplemental oxygen, ICU admission and IMV persisted with RSV as compared with COVID-19 and influenza. Risks with RSV were highest among children <1 year old. Inpatient mortality was observed [0.1% (RSV), 0.3% (COVID-19), 0.4% (influenza)]. Conclusion: Viral respiratory diseases cause a significant burden of illness in hospitalized children <5 years of age. Compared with COVID-19 and influenza, RSV had a significantly higher risk of nearly all inhospital outcomes examined. Inhospital mortality for COVID-19 and influenza was higher than RSV.